Alliance Pharma plc, (LSE.APH) the Chippenham based emerging speciality pharmaceutical company, today announced that it has signed an agreement with Valeant Pharmaceuticals Ltd to co-promote SymmetrelTM (amantadine), Alliance's treatment for Parkinson's disease alongside Valeant's MestinonTM (pyridostigmine), for the treatment of myasthenia gravis, to hospital neurologists.  The agreement will mean that both specialist sales forces will promote the benefits of Symmetrel alongside Mestinon to hospital neurologists and specialists involved in the care of the elderly.

The combined sales forces will now reach over 90% of UK neurologists with both products, creating the second largest dedicated neurology sales force in the country.  Alliance acquired the Symmetrel brand from Novartis in October 2001 and has grown the sales to its current level of £1.2m in the UK.  It is specifically aimed at treating the dyskinesias (abnormal involuntary movements) associated with Parkinson's disease which currently affects a growing population of more than 15,000 patients in the UK alone.

John Dawson, CEO of Alliance Pharma commented:

'The agreement with Valeant confirms our position as a significant force in the neurology sector and endorses our stated strategy of being the partner of choice for commercialising products from emerging biotech and global R&D companies.

Co-promotion agreements of this nature create platforms from which we can develop the sales potential within our existing range of 30 pharmaceutical brands.  This success then provides an added advantage when competing for future brands or in-licensing opportunities.'

- ends -

For further information please contact:

Alliance Pharma plc
John Dawson
CEO
01249 466966

Beattie Financial
James Chandler/Mike Wort/John Moriarty
020 7398 3300